INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Letter Agreement with Gregory S. Rush
On January3, 2018, INC Research Holdings, Inc., a Delaware corporation (the “Company”), entered into a letter agreement (the “Letter Agreement”) with Gregory S. Rush, Executive Vice President and Chief Financial Officer of the Company, to which Mr.Rush will continue to serve in that role with the Company until April30, 2018, at which time he will step down and cease to be an executive officer and employee of the Company.
As part of his transition, Mr.Rush will receive a one-time cash transition bonus equal to $400,000, payable $250,000 on the date 2017 annual bonuses are paid and $150,000 promptly after April30, 2018, subject to execution of a release of claims. Mr.Rush’s non-competition covenant, to his employment agreement with the Company, dated August5, 2013, will be deemed to run from February16, 2018.
The foregoing summary of the Letter Agreement is qualified in its entirety by reference to the agreement itself, which is attached to this Current Report as Exhibit 10.1 and which is incorporated by reference in its entirety into this Item 5.02.
Item 5.02 Financial Statements and Exhibits.
(d) Exhibits
INC Research Holdings, Inc. ExhibitEX-10.1 2 d493016dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 January 3,…To view the full exhibit click here
About INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
